Počet záznamů: 1
Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2
- 1.
SYSNO ASEP 0555182 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2 Tvůrce(i) Tonk, M. (DE)
Růžek, Daniel (BC-A) RID, ORCID
Vilcinskas, A. (DE)Celkový počet autorů 3 Číslo článku 912 Zdroj.dok. Viruses. - : MDPI
Roč. 13, č. 5 (2021)Poč.str. 12 s. Forma vydání Online - E Jazyk dok. eng - angličtina Země vyd. CH - Švýcarsko Klíč. slova virus ; inhibition ; defensin ; mice ; SARS-CoV-2 ; covid-19 ; coronavirus ; antimicrobial peptides ; antiviral peptides ; defensins Vědní obor RIV EE - Mikrobiologie, virologie Obor OECD Virology Způsob publikování Open access Institucionální podpora BC-A - RVO:60077344 UT WOS 000654600000001 EID SCOPUS 85106981267 DOI 10.3390/v13050912 Anotace Multiple outbreaks of epidemic and pandemic viral diseases have occurred in the last 20 years, including those caused by Ebola virus, Zika virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence or re-emergence of such diseases has revealed the deficiency in our pipeline for the discovery and development of antiviral drugs. One promising solution is the extensive library of antimicrobial peptides (AMPs) produced by all eukaryotic organisms. AMPs are widely known for their activity against bacteria, but many possess additional antifungal, antiparasitic, insecticidal, anticancer, or antiviral activities. AMPs could therefore be suitable as leads for the development of new peptide-based antiviral drugs. Sixty therapeutic peptides had been approved by the end of 2018, with at least another 150 in preclinical or clinical development. Peptides undergoing clinical trials include analogs, mimetics, and natural AMPs. The advantages of AMPs include novel mechanisms of action that hinder the evolution of resistance, low molecular weight, low toxicity toward human cells but high specificity and efficacy, the latter enhanced by the optimization of AMP sequences. In this opinion article, we summarize the evidence supporting the efficacy of antiviral AMPs and discuss their potential to treat emerging viral diseases including COVID-19. Pracoviště Biologické centrum (od r. 2006) Kontakt Dana Hypšová, eje@eje.cz, Tel.: 387 775 214 Rok sběru 2022 Elektronická adresa https://www.mdpi.com/1999-4915/13/5/912
Počet záznamů: 1